Abstract library

150 results for "phase 1".
#2168 Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors
Introduction: Activation of VEGFR2 and MET is implicated in driving growth of NET. Cabozantinib inhibits VEGFR2, MET, AXL, RET.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Jennifer Chan
#2075 Phase 1 Pharmacokinetic and Pharmacodynamic Study of APOC, a New Controlled Release Formulation (CRF) of 15mg Octreotide Acetate in Healthy Male Volunteers
Introduction: Somatostatin analogues (SSAs) are considered the gold standard for systemic therapy of advanced neuroendocrine tumors (NETs). Octreotide is one of the SSAs most widely used in long-term therapies of NETs. There is increasing evidence that clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products without impacting significantly the quality of life of the patients. APOC is a new injectable controlled release technology containing Octreotide invented and developed by Ascil-Biopharm and designed to cover specifically these clinical unmet needs. It is presented as ready-to-use and can easily be manufactured at selected doses and durations in prefilled syringe.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Rosa Maria Antonijoan Arbós
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#280 Sorafenib and Bevacizumab Combination Targeted Therapy in Advanced Neuroendocrine Tumor: A Phase II Study of the Spanish Neuroendocrine Tumor Group (GETNE0801)
Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Mrs. Cristina Garrido
#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)
Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Raymond
#334 Everolimus + Octreotide LAR v. Placebo + Octreotide LAR in Patients With Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)
Introduction: Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase 2 studies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Marianne Pavel
#992 Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Dr Gianluca Tamagno
#1498 Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-center, Open-label, Dose-escalation Study
Introduction: PAS, a next generation SSA, is investigated to determine the maximum tolerated dose (MTD) in pts with advanced NET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD James Yao
Authors: Yao J, Chan J, Mita A, Kundu M, ...
Keywords: Pasireotide, MTD
#2087 Prospective, Multi-Center, Open Label, Phase Study II of APOC, a New Controlled Release 15mg Octreotide Acetate, for the Treatment of Advanced NETs
Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy of advanced NETs. The efficacy controlling hormone release and tumor growth together with the favorable toxicity profile have positioned SSAs as upfront therapy. Despite of second-line therapies including targeted agents, chemotherapy and radiolabeled peptides have demonstrated activity controlling tumor growth, the less favorable toxicity profiles become a usual discussion with patients (pts) to preserve the quality of life (QoL). Additionally, from concordant flow of evidences clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products. APOC is a new controlled release ready-to-use convenient therapeutic, designed to cover specifically these clinical unmet needs.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Jaume Capdevila
#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Larry K Kvols